Author: Jones, Bryan E.; Brown-Augsburger, Patricia L.; Corbett, Kizzmekia S.; Westendorf, Kathryn; Davies, Julian; Cujec, Thomas P.; Wiethoff, Christopher M.; Blackbourne, Jamie L.; Heinz, Beverly A.; Foster, Denisa; Higgs, Richard E.; Balasubramaniam, Deepa; Wang, Lingshu; Bidshahri, Roza; Kraft, Lucas; Hwang, Yuri; Žentelis, Stefanie; Jepson, Kevin R.; Goya, Rodrigo; Smith, Maia A.; Collins, David W.; Hinshaw, Samuel J.; Tycho, Sean A.; Pellacani, Davide; Xiang, Ping; Muthuraman, Krithika; Sobhanifar, Solmaz; Piper, Marissa H.; Triana, Franz J.; Hendle, Jorg; Pustilnik, Anna; Adams, Andrew C.; Berens, Shawn J.; Baric, Ralph S.; Martinez, David R.; Cross, Robert W.; Geisbert, Thomas W.; Borisevich, Viktoriya; Abiona, Olubukola; Belli, Hayley M.; de Vries, Maren; Mohamed, Adil; Dittmann, Meike; Samanovic, Marie; Mulligan, Mark J.; Goldsmith, Jory A.; Hsieh, Ching-Lin; Johnson, Nicole V.; Wrapp, Daniel; McLellan, Jason S.; Barnhart, Bryan C.; Graham, Barney S.; Mascola, John R.; Hansen, Carl L.; Falconer, Ester
Title: LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection Cord-id: 8nu9qss9 Document date: 2020_10_9
ID: 8nu9qss9
Snippet: SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque c
Document: SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection. One Sentence Summary LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.
Search related documents:
Co phrase search for related documents- activation pre and administration sars: 1
- activation pre and lung tissue: 1
- activity block and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- activity value and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
- acute respiratory syndrome and administration sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and live cell assay: 1, 2, 3
- acute respiratory syndrome and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and load viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute respiratory syndrome and low inoculum: 1
- acute respiratory syndrome and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- administration sars and live virus: 1, 2, 3, 4
- live virus and low inoculum: 1
- live virus and low respiratory: 1, 2
- live virus and low respiratory tract: 1, 2
Co phrase search for related documents, hyperlinks ordered by date